Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7244280 | 0.85 | HTR6 (0.46) | LTB4RLTB4R2BLMTSHRPIN1 | |
| SCHEMBL31558350 | 0.84 | LTB4R (0.53) | LTB4RLTB4R2BLMTSHR | |
| SCHEMBL7249674 | 0.84 | BLM (0.41) | LTB4RLTB4R2BLMTSHR | |
| SCHEMBL7244243 | 0.81 | LTB4R (0.47) | LTB4RLTB4R2KMT2A | |
| SCHEMBL7247898 | 0.79 | GRIN2B (0.45) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL7250161 | 0.78 | OPRD1 (0.43) | BLMTSHR | |
| SCHEMBL7241734 | 0.76 | HTR6 (0.46) | LTB4RLTB4R2BLMTSHR | |
| SCHEMBL7249487 | 0.76 | HTR6 (0.46) | LTB4RLTB4R2BLMTSHR | |
| SCHEMBL7241908 | 0.75 | CYP3A4 (0.50) | LTB4RLTB4R2TSHRTAS1R3TAS1R1 | |
| SCHEMBL7242002 | 0.74 | OPRM1 (0.39) | LTB4RLTB4R2TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | GOLDSTEIN STEVEN WAYNE (US) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | CCNA1, CCNE1, CCND1 | LTB4R 3845/4885LTB4R2 4204/4885BLM 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.